Activators of LRRK2 mRNA decay and use thereof to treat Parkinson’s disease or LRRK2-related diseases

  • Parkinson’s disease is recognized as the second most common neurodegenerative disorder and the most common movement disorder
  • Unmet Need: There is no cure or proven disease-modifying therapy for Parkinson’s disease
  • Technology involves the use of a small molecule as a new approach that effectively tackles Parkinson’s disease, demonstrated in Parkinson’s disease mouse models

Contact Information

Name: Amit Kumar

Email: a.kumar@uconn.edu

Phone: (860) 486-6938